SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VAXGEN INC. (VXGN)- The IPO
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: GPSite who wrote (25)7/8/1999 12:25:00 PM
From: gary r. albrecht  Read Replies (2) of 55
 
I received the VaxGen prospectus. I found particularly interesting a couple of points.

In Phase II all humans vaccinated developed neutralizing antibodies. The level of neutralizing antibodies developed in humans exceeded that level developed in chimps. No chimp that received the vaccine became infected when injected with the virus; all chimps that did not received the vaccine and were injected with the virus became infected.

There will be an interim review of Phase III results. If the efficacy of the vaccine is shown at that time approval can be received for the marketing, i.e. don't necessarily have to wait 3 years.

gary
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News